Alvotech has entered into a strategic manufacturing partnership with LOTTE Biologics, aimed at increasing its global supply capabilities. This collaboration is significant for Alvotech as it seeks to expand its production capacity for biosimilar medicines, which are critical in addressing the growing demand for affordable biologic therapies.
Founded by Robert Wessman, Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines. The company is headquartered in Luxembourg and trades on Nasdaq under the ticker symbols ALVO and ALVOW. With a commitment to delivering high-quality, cost-effective products, Alvotech has already launched five biosimilars in various global markets, targeting conditions such as autoimmune disorders and cancer.
The recent filing, dated October 7, 2026, details the partnership with LOTTE Biologics, a contract development and manufacturing organization (CDMO). According to the filing, the agreement will enable LOTTE Biologics to produce drug substances for multiple antibody biosimilar products at its Syracuse facility in New York. This facility boasts a significant bioreactor capacity and has demonstrated strong quality and regulatory capabilities, recently passing an FDA inspection with no observations.
Lisa Graver, CEO of Alvotech, emphasized the importance of this partnership, stating, “With the expansion of our global manufacturing network, we will have sufficient capacity to meet demand for our pipeline for the next ten years.” The collaboration is designed to complement Alvotech's existing manufacturing partnerships and in-house capabilities, allowing for greater flexibility in meeting international market demands.
This strategic move may impact various stakeholders, including patients who will benefit from increased access to affordable biologic medicines. Additionally, the partnership may influence competitors in the biological products industry, as Alvotech enhances its manufacturing footprint and expands its product portfolio.
The filing does not specify what steps will follow this announcement, but the partnership is expected to undergo successful technology transfer, manufacturing qualification, and obtain necessary regulatory approvals before commercial supply begins.